As filed with the Securities and Exchange Commission on March 5, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ZAFGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 20-3857670 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
Zafgen, Inc.
3 Center Plaza, Suite 610
Boston, Massachusetts 02108
(617) 622-4003
(Address of Principal Executive Offices) (Zip Code)
Zafgen, Inc. 2014 Stock Option and Incentive Plan
(Full Title of the Plans)
Jeffrey Hatfield
Chief Executive Officer
Zafgen, Inc.
3 Center Plaza, Suite 610
Boston, Massachusetts 02108
(Name and Address of Agent For Service)
(617) 622-4003
(Telephone Number, Including Area Code, of Agent For Service)
Copy to:
Mitchell S. Bloom, Esq.
Danielle Lauzon, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth Company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Securities to be Registered |
Amount to be Registered (1) |
Proposed Maximum Offering Price per Share |
Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee | ||||
Common Stock, $0.001 par value per share |
1,497,859 shares (2) | $1.22 (3) | $1,827,387.98 |
$237.20 | ||||
| ||||||||
|
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this registration statement on Form S-8 (this Registration Statement) shall also cover any additional shares of common stock, par value $0.001 per share (the Common Stock), of Zafgen, Inc. (the Registrant), which become issuable under the Registrants 2014 Stock Option and Incentive Plan (the Plan) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrants outstanding shares of Common Stock. |
(2) | Represents an automatic increase to the number of shares available for issuance under the Plan, effective January 1, 2020. Shares available for issuance under the Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on June 19, 2014 (Registration No. 333-196900), June 12, 2015 (Registration No. 333-204931), March 15, 2016 (Registration No. 333-210216), March 10, 2017 (Registration No. 333-216602), March 9, 2018 (Registration No. 333-223561) and March 14, 2019 (Registration No. 333-230291). |
(3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on the average of the high and low sale prices of the Registrants Common Stock, as quoted on the Nasdaq Global Select Market, on March 3, 2020. |
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers additional shares of Common Stock under the Registrants 2014 Stock Option and Incentive Plan (the Plan). The number of shares of Common Stock reserved and available for issuance under the Plan is subject to an automatic annual increase on each January 1, beginning in 2015, by an amount equal to four percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Compensation Committee of the Registrants Board of Directors. Accordingly, on January 1, 2020, the number of shares of Common Stock reserved and available for issuance under the plan increased by 1,497,859. This Registration Statement registers these additional 1,497,859 shares of Common Stock. The additional shares are of the same class as other securities relating to the Plan for which the Registrants registration statement filed on Form S-8 (Registration Nos. 333-196900, 333-204931, 333-210216, 333-216602, 333-216602 and 333-230291) on June 19, 2014, June 12, 2015, March 15, 2016, March 10, 2017, March 9, 2018 and March 14, 2019 are effective. The information contained in the Registrants registration statements on Form S-8 (Registration Nos. 333-196900, 333-204931, 333-210216, 333-216602, 333-216602 and 333-230291) is hereby incorporated by reference pursuant to General Instruction E.
2
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.
3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 5th day of March, 2020.
ZAFGEN, INC. | ||
By: | /s/ Jeffrey Hatfield | |
Jeffrey Hatfield | ||
Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Jeffrey Hatfield and Patricia L. Allen as such persons true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such persons name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person in the capacities and on the date indicated.
Name | Title | Date | ||
/s/ Jeffrey Hatfield | Chief Executive Officer and Director | March 5, 2020 | ||
Jeffrey Hatfield | (Principal Executive Officer) | |||
/s/ Patricia L. Allen | Chief Financial Officer | March 5, 2020 | ||
Patricia L. Allen | (Principal Financial and Accounting Officer) | |||
/s/ Peter Barrett | Chairman of the Board of Directors | March 5, 2020 | ||
Peter Barrett, Ph.D. | ||||
/s/ Wendy Everett | Director | March 5, 2020 | ||
Wendy Everett Sc.D. | ||||
/s/ Robert J. Perez | Director | March 5, 2020 | ||
Robert J. Perez | ||||
/s/ John L. LaMattina | Director | March 5, 2020 | ||
John L. LaMattina, Ph.D. | ||||
/s/ Cameron Geoffrey McDonough | Director | March 5, 2020 | ||
Cameron Geoffrey McDonough, M.D. | ||||
/s/ Frank E. Thomas | Director | March 5, 2020 | ||
Frank E. Thomas | ||||
/s/ Thomas O. Daniel | Director | March 5, 2020 | ||
Thomas O. Daniel, M.D. |
4
EXHIBIT INDEX
* | Filed herewith. |
5
Exhibit 5.1
March 5, 2020
Zafgen, Inc.
3 Center Plaza, Suite 610
Boston, MA 02108
Re: | Securities Being Registered under Registration Statement on Form S-8 |
Ladies and Gentlemen:
We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the Registration Statement) pursuant to the Securities Act of 1933, as amended (the Securities Act), on or about the date hereof relating to an aggregate of 1,497,859 shares (the Shares) of Common Stock, $0.001 par value per share, of Zafgen, Inc., a Delaware corporation (the Company), that may be issued pursuant to the Companys 2014 Stock Option and Incentive Plan (the Plan).
We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.
The opinion set forth below is limited to the Delaware General Corporation Law.
For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.
Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.
We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
Very truly yours, |
/S/ GOODWIN PROCTER LLP |
GOODWIN PROCTER LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Zafgen, Inc. of our report dated March 5, 2020 relating to the financial statements, which appears in Zafgen, Inc.s Annual Report on Form 10-K for the year ended December 31, 2019.
/s/ PricewaterhouseCoopers LLP |
Boston, Massachusetts |
March 5, 2020 |